Skip to main content
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
Published Web Location
http://europepmc.org/articles/PMC4230393?pdf=renderNo data is associated with this publication.
Abstract
Background and objective: Pirfenidone is an oral antifibrotic agent that is approved in several countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a comprehensive analysis of safety across four clinical trials evaluating pirfe
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.